Thromboprophylaxis Discontinuation Guidelines

Introduction to Discontinuation Criteria

The American College of Chest Physicians recommends discontinuing unfractionated heparin (UFH) thromboprophylaxis when the patient regains mobility or at hospital discharge for medical patients, but continuing for 7-10 days minimum in surgical patients, with a maximum of 4 weeks for high-risk cancer surgery patients 1, 2, 3

Discontinue UFH when the acute illness resolves and the patient is no longer immobilized, as recommended by the American College of Chest Physicians (Grade 2B) 2, 3
Stop UFH when the patient becomes ambulatory, even if still hospitalized 2
Discontinue at hospital discharge for most medical patients 3, 4

Continue UFH for at least 7-10 days postoperatively or until fully ambulatory, whichever is longer, as recommended by the American College of Chest Physicians 1, 5, 6
Initiate UFH 2 hours preoperatively and maintain throughout the high-risk perioperative period 5, 6
Extended prophylaxis for up to 4 weeks is strongly recommended for patients undergoing major abdominal or pelvic surgery for cancer, particularly those with restricted mobility postoperatively, obesity, history of VTE, additional thrombotic risk factors, or metastatic disease, as recommended by the American Society of Hematology 1, 4

When transitioning from UFH to warfarin for long-term VTE treatment, continue UFH for at least 5 days and until INR ≥2.0 is achieved before discontinuing, as recommended by the National Comprehensive Cancer Network 7, 8
Measure INR at least twice weekly during the transition period 8
In patients with severe renal impairment (CrCl <30 mL/min), UFH remains the preferred agent and can be continued as long as thrombotic risk persists, with no dose adjustment required for renal dysfunction 5, 6, 7, 8
If clinically significant bleeding develops, stop UFH immediately and switch to mechanical prophylaxis until bleeding risk decreases, then resume pharmacologic prophylaxis when bleeding risk has sufficiently diminished and VTE risk persists, as recommended by the American College of Chest Physicians 2, 3

Do not stop UFH prematurely in cancer surgery patients at hospital discharge if they remain at high risk, as this increases VTE risk, as warned by the American Society of Hematology 1, 4
Do not continue prophylaxis indefinitely in medical patients beyond mobility restoration, as this increases bleeding risk without proven benefit, as warned by the American College of Chest Physicians 3
Monitor platelet counts every 2-3 days from day 4 to day 14 and stop immediately if heparin-induced thrombocytopenia (HIT) is suspected, as recommended by the National Comprehensive Cancer Network 5, 6
Never use UFH in patients with active or history of HIT, and switch to a direct thrombin inhibitor or fondaparinux instead, as recommended by the National Comprehensive Cancer Network 5, 7, 8